Robert W. Baird Begins Coverage on Dyne Therapeutics (NASDAQ:DYN)

Investment analysts at Robert W. Baird began coverage on shares of Dyne Therapeutics (NASDAQ:DYN) in a report released on Friday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $46.00 price target on the stock. Robert W. Baird’s price target indicates a potential upside of 78.78% from the company’s previous close.

Several other research analysts have also issued reports on the company. StockNews.com lowered Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. Chardan Capital restated a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $53.00 price objective on shares of Dyne Therapeutics in a research report on Monday, September 23rd. JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. Finally, Royal Bank of Canada assumed coverage on shares of Dyne Therapeutics in a research note on Tuesday, November 26th. They set an “outperform” rating and a $45.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Dyne Therapeutics has an average rating of “Moderate Buy” and an average price target of $50.42.

Dyne Therapeutics Trading Up 0.5 %

DYN opened at $25.73 on Friday. The firm has a market cap of $2.62 billion, a price-to-earnings ratio of -7.23 and a beta of 1.09. Dyne Therapeutics has a 12 month low of $11.51 and a 12 month high of $47.45. The stock has a fifty day moving average price of $30.39 and a 200-day moving average price of $35.23.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, equities research analysts forecast that Dyne Therapeutics will post -3.45 EPS for the current year.

Insider Buying and Selling

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,334 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $65,632.08. Following the transaction, the insider now owns 201,685 shares in the company, valued at approximately $5,671,382.20. This trade represents a 1.14 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Jason P. Rhodes sold 782 shares of Dyne Therapeutics stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $33.10, for a total transaction of $25,884.20. Following the sale, the director now directly owns 15,962 shares in the company, valued at approximately $528,342.20. This trade represents a 4.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 180,046 shares of company stock worth $6,300,265 in the last 90 days. Insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new stake in shares of Dyne Therapeutics in the 2nd quarter valued at $217,000. Nisa Investment Advisors LLC raised its stake in Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after acquiring an additional 669 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Dyne Therapeutics by 52.5% in the second quarter. Bank of New York Mellon Corp now owns 311,504 shares of the company’s stock valued at $10,993,000 after acquiring an additional 107,233 shares during the last quarter. Legato Capital Management LLC boosted its stake in Dyne Therapeutics by 35.3% in the second quarter. Legato Capital Management LLC now owns 15,480 shares of the company’s stock valued at $546,000 after acquiring an additional 4,035 shares in the last quarter. Finally, Lisanti Capital Growth LLC grew its holdings in shares of Dyne Therapeutics by 22.5% during the second quarter. Lisanti Capital Growth LLC now owns 106,140 shares of the company’s stock worth $3,746,000 after purchasing an additional 19,530 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.